Immunotherapy represents a major breakthrough of systemic anti-cancer therapy for multiple cancer types. Several types of immunotherapies that can improve the hosts’ immune response against cancer have shown promising anti-cancer activities in clinical trials. These therapy include immune checkpoint inhibitors, adoptive cell therapy, and T cells with chimeric antigen receptors (CARTs). The adoptive cell therapy Sipuleucel-T has shown survival benefit in patients with metastatic, castrate-resistant prostate cancer. Several types of immune checkpoint inhibitors have been developed, including antibodies that block the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell death protein 1 (PD-1) pathways. The anti-CTLA-4 antibody ipilimumab was the first agent approved in the EU and USA for the treatment of adult patients with unresectable or metastatic melanoma who have received prior therapy.? that showed an overall survival benefit in a randomized phase III trial. The anti-PD-1 antibodies nivolumab and pembrolizumab have also shown promising results in melanoma and non-small cell lung cancer. Treatment with CARTs has shown striking efficacy in patients with refractory B cell leukemia and studies in many cancer types are ongoing. In this presentation the major progress of immunotherapy for cancer treatment will be summarized. Future prospects of clinical trials of immunotherapy will be discussed.